The dedicated formulation and process facility will enable Lamellar to meet the need for increased capacity as its technology attracts growing interest from external partners and it progresses its own in-house development projects.
Glasgow, UK – 27th March 2019 - Lamellar Biomedical Ltd (Lamellar), an innovative biotechnology company pioneering new approaches for the safe and effective transfer of functional nucleic acids with its LAMELLASOME™ NAT platform, announces the creation of additional capacity through its expansion into the BioCity biotech incubator, Glasgow. The dedicated formulation and process facility will enable Lamellar to meet the need for increased capacity as its technology attracts growing interest from external partners and it progresses its own in-house development projects.
Alec McLean, CEO of Lamellar, said: “We are delighted to be moving into BioCity and our new formulation and process facility. This move comes at a key time for Lamellar as the potential of our nucleic acid transfer technology is attracting growing interest. This larger facility allows us to meet our product demands needed to support our multiple collaborations with pharma and biotech companies seeking improved delivery of their active agent nucleic acids. It will also allow us to progress our own in-house development activities which are focused on novel products for Idiopathic Pulmonary Fibrosis (IPF) and Cystic Fibrosis (CF).”
Lamellar believes that this expansion will enhance its in-house capabilities, reduce reliance on external contract organisations and maximise its research & development efforts, particularly in formulation and process development studies for its LAMELLASOME™ Nucleic Acid Transfer (NAT) platform.
BioCity Glasgow is a 20-acre biotech incubator based on the site of a former MSD research facility and currently home to approximately 30 companies. It offers flexible and modular laboratory space built to exceptionally high specification. The Lamellar Biomedical facility is equipped with all the bench scale formulation, process and analytical equipment necessary to explore the full potential of the LAMELLASOME technology and the novel products being developed based on this industry-leading NAT platform.
| For further information, please contact: | |
| Lamellar Biomedical | |
| Dr Alec McLean | +44 (0) 1698 748 832 +44 (0) 1698 532 163 |
| Citigate Dewe Rogerson | |
| David Dible/ Pip Batty/Shabnam Bashir | |
About Lamellar Biomedical
Lamellar Biomedical Limited (Lamellar), is an innovative biotechnology company, pioneering new approaches for the transfer of functional nucleic acids. The Company’s unique and versatile LAMELLASOME™ platform has been designed for the safe and effective delivery of nucleic acid-based therapeutics. Lamellar believes that its LAMELLASOME technology will play a key role in realising the potential of mRNAs, siRNAs, miRs, plasmids and other nucleic acids in development offering the potential to revolutionise the treatment of many rare and intractable diseases.
LAMELLASOME formulations have been shown to be effective in delivering functional nucleic acids to a range of cell types including macrophages, human pulmonary fibroblasts and human dendritic cells. The technology has also been successfully used for the in vivo delivery of functional nucleic acids.
Lamellar is developing its own pipeline of nucleic acid-based therapeutics, the most advanced of which target two areas of unmet clinical need: Idiopathic Pulmonary Fibrosis and Cystic Fibrosis.
Founded in 2007, Lamellar is backed by both institutional and private investors, including Invesco, Scottish Enterprise, Barwell Plc, TRI Capital and has multiple research collaborations with world renowned institutions and universities.
About LAMELLASOME™
LAMELLASOME™ technology comprises synthetic lipid vesicles with compositions based on human lamellar bodies/exosomes. LAMELLASOME technology represents a considerable advance in safe and effective non-viral transfection and is distinct from cationic and divalent-ion liposomal systems. LAMELLASOME monotherapy formulations have excellent preclinical safety, a very high NOAEL (taken from inhalation toxicology) and excellent clinical safety and tolerability profile.
Lamellar Biomedical can construct novel and bespoke LAMELLASOME formulations and thus optimise the delivery of specific active-agent nucleic acids.
Lamellar Biomedical intends to tailor its LAMELLASOME technology to safely and effectively deliver nucleic acid-based therapeutics to their target cells in order to optimise their functionality.
